Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Preferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bruker (BRKR) EBT (2016 - 2026)

Bruker filings provide 16 years of EBT readings, the most recent being $386.1 million for Q4 2025.

  • On a quarterly basis, EBT rose 26.05% to $386.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $339.9 million, a 25.64% decrease, with the full-year FY2025 number at $339.9 million, down 25.64% from a year prior.
  • EBT hit $386.1 million in Q4 2025 for Bruker, up from -$71.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $386.1 million in Q4 2025 to a low of -$306.2 million in Q4 2022.
  • Median EBT over the past 5 years was $78.8 million (2021), compared with a mean of $65.6 million.
  • Biggest five-year swings in EBT: surged 531.85% in 2021 and later plummeted 229.84% in 2025.
  • Bruker's EBT stood at -$289.5 million in 2021, then fell by 5.77% to -$306.2 million in 2022, then soared by 178.67% to $240.9 million in 2023, then increased by 27.15% to $306.3 million in 2024, then rose by 26.05% to $386.1 million in 2025.
  • The last three reported values for EBT were $386.1 million (Q4 2025), -$71.8 million (Q3 2025), and $500000.0 (Q2 2025) per Business Quant data.